Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Bets Big On Oncology In New R&D Strategy

Executive Summary

The big pharma will establish a new oncology unit focused on bringing its anti-PD-1 immunotherapy MK-3475 to market as part of a massive R&D overhaul aimed at lowering costs while driving innovation. Merck isn’t one of the industry’s leading oncology players and may not have as much R&D expertise in the area as rivals, but it might not ultimately matter – as long as MK-3475 gets to market.

Advertisement

Related Content

Merck’s Oncology Strategy: Digging In With Expansion Of Keytruda
Focus On The Core: Merck Claims R&D Restructuring Poised To Produce Results
Focus On The Core: Merck Claims R&D Restructuring Poised To Produce Results
Merck Expands Immuno-Oncology Efforts, Calls MK-3475 A Pipeline In Itself
Merck Moves Forward With Odanacatib Filing; FDA Accepts MK-3475 Filing
Big Pharma Explores New Frontier Of Lung Cancer Immunotherapy
FDA Needs More Time To Review Sugammadex Inspection Report, Cancels Advisory Committee
Melanoma Success Paves Way For Path Of Gold In Cancer Immunotherapy
Merck/AstraZeneca Stay Tied To Each Other For Another Two Years
Schering’s Organon Grab Made Merck's Merger Magic Happen

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS055645

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel